Warehousing and distribution drug supply UK/US/Europe: We work closely with you to provide market insights needed in order to implement the best strategy to meet your commercial drug supply requirements. Our client testimonials attest to our unique, collaborative approach, which adds longstanding value and strong partnerships. Our aim is to understand your goals and to work to minimize waste, allowing you to reinvest those savings back into your R&D initiatives. We hold ourselves to the highest standards, delivering on time, and most importantly, with uncompromised quality and integrity. Discover additional info on https://www.clientpharma.com/risk-mitigation-and-competitiveness/.
We profoundly understand and recognize the numerous risks associated with global drug procurement. We also appreciate the many complexities associated with worldwide storage and distribution of clinical trial supplies. Our team knows the importance of an efficient, robust supply chain — audited & approved — that promotes excellence, security and accountability. We provide batch traceability, supporting documentation (i.e. Certificates of Analysis (CofAs), Batch Release Certificates (BRCs), GMP Statements, stability data, Fit-for-Use (FFU) Statements, Certificates of Conformance (CofCs), Certificates of Origin (CofOs), etc.) and temperature monitoring data – delivering product pedigree and authenticity.
Experts in accessing biosimilars and reference medicines that others cannot. We pride ourselves on the ability to access commercial medicines that others cannot, especially from challenging markets while always providing premier service and excellent, consultative guidance throughout your project. We overcome your comparator sourcing challenges. ClientPharma’s clinical trial project management team brings proficiency in overseeing and overcoming your commercial drug supply challenges.
Our temperature-controlled capabilities include 2°- 8°C and 15°- 25°C facilities, as well as access to specialist transport to manage deliveries around the world according to product temperature requirements. Extensive capabilities: Our capabilities include stock receipt, import & export expertise, in-territory regulatory specialists, product reconciliation and destruction services. You can trust us: Our highly trained logistics team is dedicated to providing a robust clinical trial supply chain and trusted product integrity with regulatory compliant distribution through validated temperature-controlled logistics. We provide the peace-of-mind you need, offering you with dedicated clinical trial supply chain solutions to meet the explicit needs of your clinical programs. Find more information at https://www.clientpharma.com/.
Andrea Chopek, President, North America at ClientPharma relayed, “Our industry is yearning for a sleek, global approach for commercial drug supply — and with this strategic partnership, we offer that. Together, we solve drug supply difficulties and navigate the many complexities — reducing supply chain risks and managing waste and costs throughout the stages of your clinical trial. Two industry leaders coming together doesn’t dilute the solution, it provides one concentrated, easy solution for our clients.” TrialCard Incorporated is a full-service life sciences commercialization partner that provides comprehensive solutions that span the entire biopharmaceutical value chain. In addition to a foundation of fully integrated, digitally enabled patient support services, its broader offerings include everything from late-stage clinical trial management to post-marketing HCP engagement services and proprietary data-as-a-service payer intelligence and insights. Founded in 2000, TrialCard provides commercialization needs for more than 160 life science customers and has connected over 35 million patients with more than $18 billion in branded drug savings to date. The company is headquartered in Morrisville, North Carolina.
Forecasts by their very definition involve a degree of uncertainty. When a company fails to meet demand it can have major implications on the drug and the pharmaceutical company. The company may experience loss in sales, a bad reputation for unreliability with customers and overworked employees. It has been reported that where the drug itself is concerned, if the launch of a medicine is delayed due to a failure in estimation, it costs on average $15 million per drug, per day. Further research has also shown that a blockbuster drug will lose $1 billion in revenue annually until capacity is developed to meet demand. Overestimations in demand generally happen when the market is at its most volatile, or, if the reach of a new drug has been over estimated. These inaccuracies can cost companies. If a product’s demand is overestimated, companies have to find ways to correct their misjudgement by cutting the price of medicines which reduces margins and by making employees redundant to pay for the excess of stock. In some cases companies also have to destroy stock that has not been sold.